The abstract is read at the publisher; the summary is JClub's.
In 365 patients with non-small cell lung cancer harboring KRAS Q61 mutations, median overall survival was 12.3 months, with first-line immunotherapy linked to longer survival.
- Why it matters: KRAS Q61 mutations form a heterogeneous NSCLC subgroup, but their prognosis and which treatment regimens yield better outcomes remain unclear.
- What they did: From 2011–2023, diagnostic samples were profiled by next-generation sequencing, then molecular features were matched to clinical records using Kaplan-Meier time-to-event analyses.
- The result: Q61H (74.0%) and Q61L (20.8%) showed distinct co-mutation patterns and survival; immunotherapy (monotherapy or combined) prolonged real-world progression-free survival versus chemotherapy in first line (P < 0.01), especially with PD-L1 tumor proportion score ≥50%.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.